Merit E Cudkowicz
Overview
Explore the profile of Merit E Cudkowicz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
136
Citations
5398
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Berry J, Maragakis N, Macklin E, Chibnik L, Quintana M, Saville B, et al.
JAMA
. 2025 Mar;
PMID: 40067821
Importance: Bioenergetic failure has been proposed as a driver of amyotrophic lateral sclerosis (ALS). CNM-Au8 is a suspension of gold nanocrystals that catalyzes the conversion of nicotinamide adenine dinucleotide hydride...
2.
Shefner J, Oskarsson B, Macklin E, Chibnik L, Quintana M, Saville B, et al.
JAMA
. 2025 Mar;
PMID: 40067755
Importance: Amyotrophic lateral sclerosis (ALS) is a fatal disease. The sigma-1 (σ1) receptor emerged as a target for intervention. Objective: To determine the effects of pridopidine, a σ1-receptor agonist, in...
3.
Verdiperstat in Amyotrophic Lateral Sclerosis: Results From the Randomized HEALEY ALS Platform Trial
Andrews J, Paganoni S, Macklin E, Chibnik L, Quintana M, Saville B, et al.
JAMA Neurol
. 2025 Mar;
PMID: 40067754
Importance: Myeloperoxidase is one of the most abundant peroxidase enzymes in activated myeloid cells. Myeloperoxidase inhibitors may have a clinical benefit in amyotrophic lateral sclerosis (ALS) by slowing neurodegeneration via...
4.
Paganoni S, Fournier C, Macklin E, Chibnik L, Quintana M, Saville B, et al.
JAMA Netw Open
. 2025 Feb;
8(2):e2459058.
PMID: 39960672
Importance: The etiology of amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease, is unknown. However, neuroinflammation and complement activation may play a role in disease progression. Objective: To determine the...
5.
Howard I, Babu S, Carter C, Sakowski S, Kurent J, Cudkowicz M, et al.
Ann Neurol
. 2024 Oct;
96(6):1035-1039.
PMID: 39390661
Amyotrophic lateral sclerosis (ALS) is a relentless, fatal neurodegenerative disease. The progressive loss of voluntary muscle function, diagnostic delays, lack of effective treatments, and challenges accessing multidisciplinary care and resources...
6.
7.
Neel D, Baselga-Garriga C, Benson M, Keegan M, Chase M, DAgostino D, et al.
Muscle Nerve
. 2024 Jun;
70(2):232-239.
PMID: 38842106
Introduction/aims: Expanded access (EA) is a Food and Drug Administration-regulated pathway to provide access to investigational products (IPs) to individuals with serious diseases who are ineligible for clinical trials. The...
8.
Lindborg S, Goyal N, Katz J, Burford M, Li J, Kaspi H, et al.
Muscle Nerve
. 2024 Apr;
69(6):719-729.
PMID: 38593477
Introduction/aims: Biomarkers have shown promise in amyotrophic lateral sclerosis (ALS) research, but the quest for reliable biomarkers remains active. This study evaluates the effect of debamestrocel on cerebrospinal fluid (CSF)...
9.
Raghav Y, Dilliott A, Petrozziello T, Kim S, Berry J, Cudkowicz M, et al.
Muscle Nerve
. 2024 Feb;
69(4):477-489.
PMID: 38305586
Introduction/aims: Genetics is an important risk factor for amyotrophic lateral sclerosis (ALS), a neurodegenerative disease affecting motor neurons. Recent findings demonstrate that in addition to specific genetic mutations, structural variants...
10.
Bjornevik K, Cortese M, Furtado J, Paganoni S, Schwarzschild M, Cudkowicz M, et al.
Neurology
. 2023 Jun;
101(7):e690-e698.
PMID: 37344230
Background And Objectives: Polyunsaturated fatty acids (PUFAs) have neuroprotective and anti-inflammatory effects and could be beneficial in amyotrophic lateral sclerosis (ALS). Higher dietary intake and plasma levels of PUFAs, in...